Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Tudorza Pressair, Eklira Genuair
Aclidinium bromide is a long-acting muscarinic antagonist (LAMA) used in the management of chronic obstructive pulmonary disease (COPD). It works by blocking the action of acetylcholine at muscarinic receptors in the lungs, leading to bronchodilation and improved airflow. It is administered as a dry powder inhaler.
For maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema.
Outcome:
Increased anticholinergic effects (e.g., dry mouth, constipation, urinary retention)
Mechanism:
Additive anticholinergic effects
Outcome:
Additive bronchodilator effects
Mechanism:
Synergistic bronchodilation
Outcome:
Potential for additive hypokalemia
Mechanism:
Increased potassium excretion
Most likely new formulation: Once-daily dry powder inhaler with improved lung deposition (Year: 2026, 60% confidence)
Based on current usage trends and clinical trial data, there is a low ( <5%) likelihood of regulatory changes regarding aclidinium's approved indications in the next 2 years.
Muscarinic Antagonist, Bronchodilator
Quinuclidine Derivative